| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Z655863-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $86.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1 , AMPK α2β1γ1 , AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC 50 s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively. In Vitro ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). AMPK activation by ZLN024 requires the pre-phosphorylation of Thr-172 by at least one upstream kinase and protects AMPK Thr-172 against dephosphorylation by PP2Cα. ZLN024 activates AMPK in L6 myotubes and stimulates glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. Using the established scintillation proximity assay (SPA) assay, random screening against the AMPK α1β1γ1 heterotrimer is performed and a new AMPK activator, ZLN024 is found. ZLN024 directly activates recombinant AMPK α1β1γ1 and its homologue α2β1γ1 in a concentration-dependent manner. ZLN024 increases the activity of α1β1γ1 by 1.5-fold and has an EC 50 of 0.42 µM, and it increases the activity of α2β1γ1 by 1.7-fold with an EC 50 of 0.95 µM. ZLN024 also directly activates recombinant AMPK α1β2γ1, by 1.7-fold with an EC 50 of 1.1 µM; and AMPK α2β2γ1, by 1.6-fold with an EC 50 of 0.13 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo C57BKS db/db mice are administered a 15 mg/kg/day dose of ZLN024 by daily gavage for 5 weeks; 250 mg/kg/day Metformin (Met) is used as a positive control. During the treatment period, there is no significant alteration in food intake and body weight compared with the vehicle group. After 4 weeks of treatment, ZLN024 improves glucose tolerance. ZLN024 reduces the fasting blood glucose by 15%. Liver tissue weight, triacylglycerol and the total cholesterol content are decreased . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:AMPK α2β2γ1 0.13 μM (EC 50 ) AMPK α1β1γ1 0.42 μM (EC 50 ) AMPK α2β1γ1 0.95 μM (EC 50 ) |
| Canonical SMILES | CC1=CC(=C(C=C1)OCCSC2=NC=CC=N2)Br.Cl |
|---|---|
| Molecular Weight | 361.69 |
Enter Lot Number to search for COA:
